Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Stopped early · Phase 1/Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

Primary Phase I:To determine dose limiting toxicities and maximum tolerated dose (MTD) of the oral administration of hydroxychloroquine (HCQ) in conjunction with transarterial chemoembolization (TACE) in treating hepatocellular carcinoma (HCC). A conventional 3+3 design will be utilized. Primary Phase II: To evaluate the complete response rate in a cohort of patients treated at the MTD, A Simon's Optimal Two-stage design will be utilized.

Key facts

Study ID

NCT02013778

Run by

Abramson Cancer Center at Penn Medicine

People needed

8

Starts

2013-11-01

Expected to finish

2019-02-01

Last updated by the study team

2020-04-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient capable of giving informed consent
• Patient diagnosed with hepatocellular carcinoma in both lobes of the liver by one of the following methods (Pathologically confirmed HCC by biopsy or HCC 2 cm with classic radiographic findings of arterial phase enhancement with venous phase washout and pseudocapsule formation on contrast enhanced MRI or CT or Lesion greater than 2 cm with probable imaging features of HCC and imaging findings of cirrhosis and/or portal hypertension or a serum alphafetoprotein (AFP) greater than 200 mg/mL.
• Patient not candidate for orthotopic liver transplantation at the Hospital of the University of Pennsylvania based on review of patient imaging and history at multidisciplinary Hepatic Tumor Conference at the Hospital of the University of Pennsylvania.
• Age 18 years old
• Albumin 2.4 g/dL; Total bilirubin 2 mg/dL; INR 1.5
• Creatinine 2.0 mg/dL, AST 121 IU/L; ALT 189 IU/L
• Child-Turcotte-Pugh Classification A or B
• Eastern Clinical Oncology Group performance status 0 or1.

You may not qualify if…

• Prior TACE
• Active GI hemorrhage within 2 weeks of study enrollment
• Ascites refractory to medical therapy
• Contraindication to receiving HCQ or TACE
• Unilobar HCC
• Contraindication to contrast enhanced MRI (i.e. unable to undergo follow-up imaging)
• Women who are pregnant
• Participation in another concurrent treatment protocol

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.